stock broking firms              
Stock market information
stock market advisory services online commodity trading
Equity Commodity and Currency
Equity > Corporate Actions > BSE Announcements
Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Decitabine Injection 50 mg single-use sterile vial from the United States Food and Drug Administration (US FDA) to market generic version of Otsuka America Pharmaceutical Inc.'s Dacogen®.

Cipla's Decitabine Injection 50 mg/vial is AP-rated and is generic equivalent of Otsuka America Pharmaceutical Inc.'s, Dacogen®. It is indicated for treatment of patients with myelodysplastic syndromes (MDS). The product is available for shipping immediately.

Dacogen® and its generic equivalents had U.S. sales of approximately $180M for the 12-month period ending September 2017, as reported by IMS Health.

Gammon India
The Board of Gammon India at its meeting held on 20 November 2017 has accorded its approval for entering into an agreement for sale of its step down subsidiary 'SAE Powerlines S.r.l' (which is held through ATSL Holdings BV) to Sterling & Wilson International FZE.

SAE Powerlines S.r.l, is a limited liability company incorporated under the laws of Italy, and is in the business of building Power Transmission and Distribution lines. Sterling & Wilson International FZE is a subsidiary of M/s Sterling & Wilson.

Guj. Automotive
Gujarat Automotive Gears will hold a meeting of the Board of Directors of the Company on 27 November 2017, to approve the Unaudited Financial Results of the Company for the quarter and half year ended on 30th September, 2017.
GlaxoSmith C H L
GlaxoSmithkline Consumer Healthcare announced that Horlicks Limited has nominated Saluja as a Nominee Director on the Board of the Company with effect from 01 January 2018 in place of Manoj Kumar who has decided to pursue his personal interests outside of the Company.
HSIL announced that ICRA has put the outstanding ICRA A1+ (ICRA A one plus) on rating watch with developing implication for the captioned borrowing programme i.e Rs. 300 crore Commercial Paper (CP) programme of the company.